Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

G1 Therapeutics Inc (GTHX)

G1 Therapeutics Inc (GTHX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies Newswire.ca - Fri Sep 20, 10:08AM CDT

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

ONCY : 1.0300 (+3.15%)
ACLX : 87.22 (-0.42%)
ONC.TO : 1.40 (-5.41%)
GTHX : 7.15 (unch)
HALO : 45.50 (-0.57%)
SNY : 47.64 (-0.29%)
Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases BayStreet.ca - Thu Apr 11, 8:49AM CDT

USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common...

ONCY : 1.0300 (+3.15%)
ONC.TO : 1.40 (-5.41%)
GILD : 88.80 (+0.19%)
GTHX : 7.15 (unch)
AZN : 63.78 (+0.92%)
HOLX : 78.04 (-0.67%)
Biotech Innovations Paving the Way in Breast Cancer Fight FinancialNewsMedia - Thu Apr 11, 8:15AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END

ONCY : 1.0300 (+3.15%)
ONC.TO : 1.40 (-5.41%)
GILD : 88.80 (+0.19%)
GTHX : 7.15 (unch)
AZN : 63.78 (+0.92%)
HOLX : 78.04 (-0.67%)
First Prescription for COSELA® (trilaciclib) Issued in China PR Newswire - Thu Feb 9, 2023

/PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics, Inc., (Nasdaq:...

GTHX : 7.15 (unch)
Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS) PR Newswire - Wed Nov 30, 2022

/PRNewswire/ -- USA News Group - A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of...

ONC.TO : 1.40 (-5.41%)
ONCY : 1.0300 (+3.15%)
LLY : 751.01 (-0.32%)
NEO : 15.36 (unch)
ZYME : 15.65 (+7.56%)
GTHX : 7.15 (unch)
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS) FinancialNewsMedia - Wed Nov 30, 2022

EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END

ONCY : 1.0300 (+3.15%)
ONC.TO : 1.40 (-5.41%)
LLY : 751.01 (-0.32%)
NEO : 15.36 (unch)
ZYME : 15.65 (+7.56%)
GTHX : 7.15 (unch)
Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio BayStreet.ca - Wed Nov 30, 2022

USA News Group – A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year’s...

ONCY : 1.0300 (+3.15%)
ONC.TO : 1.40 (-5.41%)
LLY : 751.01 (-0.32%)
NEO : 15.36 (unch)
ZYME : 15.65 (+7.56%)
GTHX : 7.15 (unch)
G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript Motley Fool - Thu Aug 4, 2022

GTHX earnings call for the period ending June 30, 2022.

GTHX : 7.15 (unch)
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights Globe Newswire - Wed Aug 3, 2022

- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue - - Completed...

GTHX : 7.15 (unch)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Mon Aug 1, 2022

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...

GTHX : 7.15 (unch)

Barchart Exclusives

Nvidia Stock: Why Any Pullback is a Buying Opportunity Barchart - 6 minutes ago
Nvidia’s outlook for Q4 revenue came in slightly below analysts' forecasts and its margins are under pressure, prompting a modest dip 2.5% in after-hours trading. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot